Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
Abstract Background CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tiss...
Main Authors: | Wilhelm K. Aicher, M. Korn, L. Reitnauer, F. B. Maurer, J. Hennenlotter, P. C. Black, T. Todenhofer, J. Bedke, A. Stenzl |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | BMC Urology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12894-021-00829-0 |
Similar Items
-
Elevated Expression of the Immune Checkpoint Ligand CD276 (B7‐H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation
by: Abruzzese, T., et al.
Published: (2022) -
Expression of immune checkpoint ligand CD276 (B7-H3) is regulated in urothelial carcinoma on a transcriptional and post-transcriptional level and drops significantly in late stage tumor tissue samples
by: W. Aicher, et al.
Published: (2020-07-01) -
The Role of CD276 in Cancers
by: Shengzhuo Liu, et al.
Published: (2021-03-01) -
An epidemiologic study on urothelial carcinomas of bladder
by: Ayşenur Keleş, et al.
Published: (2011-09-01) -
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
by: Stenehjem DD, et al.
Published: (2018-09-01)